Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis

Timothy M Dempsey^{1

2}, Viengneesee Thao², David A Helfinstine Jr², Yu-Hui H Chang³, Lindsey Sangaralingham^{2

4}, Andrew H Limper⁵

Affiliations

¹ David Grant Medical Center, US Air Force, Travis AFB, Fairfield, CA, USA Dempsey.Timothy@mayo.edu.
² Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
³ Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
⁴ OptumLabs, Cambridge, MA, USA.
⁵ Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.

Free article

Timothy M Dempsey et al. Eur Respir J. 2023.

Free article

. 2023 Oct 12;62(4):2301299.

doi: 10.1183/13993003.01299-2023. Print 2023 Oct.

Timothy M Dempsey^{1

2}, Viengneesee Thao², David A Helfinstine Jr², Yu-Hui H Chang³, Lindsey Sangaralingham^{2

4}, Andrew H Limper⁵

¹ David Grant Medical Center, US Air Force, Travis AFB, Fairfield, CA, USA Dempsey.Timothy@mayo.edu.
² Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
³ Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
⁴ OptumLabs, Cambridge, MA, USA.
⁵ Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.

No abstract available

Conflict of interest statement

Conflict of interest: The authors have no potential conflicts of interest to disclose.